文献速递头颈外科

抗C1GALT1自身抗体是头颈癌患者的新型预后生物标志物

Anti-C1GALT1 Autoantibody Is a Novel Prognostic Biomarker for Patients With Head and Neck Cancer.
PubMed 文献 · Laryngoscope · 2020-05-19

这项回顾性研究纳入186例头颈鳞状细胞癌(HNSCC)患者,中位随访55.7个月,采用ELISA检测抗C1GALT1肽自身抗体滴度。结果显示,高滴度是远处转移和疾病特异性生存不良的独立标志物;在19例接受纳武利尤单抗或帕博利珠单抗的复发或转移性(R/M)HNSCC患者中,较高滴度与更好的治疗反应相关。

要点

  • 抗C1GALT1自身抗体高滴度是HNSCC远处转移的独立标志物。
  • 高滴度与HNSCC患者疾病特异性生存不良独立相关。
  • 在19例接受免疫检查点抑制剂治疗的R/M HNSCC患者中,较高滴度与更好治疗反应相关。

核心结论

  • 抗C1GALT1自身抗体可作为HNSCC患者远处转移的新型生物标志物。
  • 该抗体对考虑免疫治疗的R/M HNSCC患者个体化医疗也有用。

研究设计与样本

  • 采用ELISA检测针对C1GALT1肽的自身抗体滴度。
  • 使用Student t检验、Kaplan-Meier分析及单因素和多因素Cox比例风险模型评估抗体滴度与临床病理因素、生存及免疫治疗反应的相关性。

主要发现

  • 高水平的抗C1GALT1自身抗体是HNSCC患者远处转移的独立标志物。
  • 高水平的抗C1GALT1自身抗体是HNSCC患者疾病特异性生存不良的独立标志物。
  • 在19例接受纳武利尤单抗或帕博利珠单抗治疗的R/M HNSCC患者中,较高自身抗体滴度与更好的治疗反应相关。

临床怎么用

  • 可考虑检测抗C1GALT1自身抗体滴度以辅助评估HNSCC患者远处转移风险及疾病特异性生存预后。
  • 对考虑免疫检查点抑制剂治疗的R/M HNSCC患者,可参考该抗体滴度辅助个体化治疗决策。

局限性

  • 证据等级为IV级。
  • 为回顾性研究。
  • 免疫治疗反应分析仅基于19例R/M HNSCC患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The objective of this study is to determine the value of the anti- glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GALT1) autoantibody as a biomarker for distant metastasis and good response to immune checkpoint inhibitors in patients with head and neck squamous cell carcinoma (HNSCC). METHODS: In this retrospective study with a median follow-up of 55.7 months, 186 HNSCC patients were enrolled between July 2013 and August 2014. Data were analyzed between April 2018 and November 2019. Titers of autoantibody against the C1GALT1 peptide were measured by ELISA. Student t test, Kaplan-Meier analysis, and univariate and multivariate Cox proportional hazard models were used to evaluate the association of anti-C1GALT1 autoantibody titer with clinicopathologic factors, survival, and response to immunotherapy. RESULTS: Our results showed that high levels of the anti-C1GALT1 autoantibody is an independent marker for distant metastasis and poor disease-specific survivals in HNSCC patients. In 19 recurrent or metastatic (R/M) HNSCC patients who have received nivolumab or pembrolizumab, higher autoantibody titers are associated with a better treatment response. CONCLUSION: We propose that the anti-C1GALT1 autoantibody can serve as a novel biomarker for distant metastasis in HNSCC patients. It is also useful in individualized medicine for R/M HNSCC patients who are considering immunotherapy. LEVEL OF EVIDENCE: IV Laryngoscope, 131:E196-E202, 2021.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Lin MC, Huang MC, Lou PJ, et al. Anti-C1GALT1 Autoantibody Is a Novel Prognostic Biomarker for Patients With Head and Neck Cancer. Laryngoscope. 2020. PMID: 32427353. doi:10.1002/lary.28694

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。